Related Experiment Video
Updated: Nov 21, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
CCDC167 as a potential therapeutic target and regulator of cell cycle-related networks in breast cancer
Pin-Shern Chen1, Hui-Ping Hsu2, Nam Nhut Phan3
1Department of Biotechnology, Chia Nan University of Pharmacy and Science, Tainan 70101, Taiwan, Republic of China.
Abstract:
According to cancer statistics reported in 2020, breast cancer constitutes 30% of new cancer cases diagnosed in American women. Histological markers of breast cancer are expressions of the estrogen receptor (ER), the progesterone receptor (PR), and human epidermal growth factor receptor (HER)-2. Up to 80% of breast cancers are grouped as ER-positive, which implies a crucial role for estrogen in breast cancer development. Therefore, identifying potential therapeutic targets and investigating their downstream pathways and networks are extremely important for drug development in these patients. Through high-throughput technology and bioinformatics screening, we revealed that coiled-coil domain-containing protein 167 (CCDC167) was upregulated in different types of tumors; however, the role of CCDC167 in the development of breast cancer still remains unclear. Integrating many kinds of databases including ONCOMINE, MetaCore, IPA, and Kaplan-Meier Plotter, we found that high expression levels of CCDC167 predicted poor prognoses of breast cancer patients. Knockdown of CCDC167 attenuated aggressive breast cancer growth and proliferation. We also demonstrated that treatment with fluorouracil, carboplatin, paclitaxel, and doxorubicin resulted in decreased expression of CCDC167 and suppressed growth of MCF-7 cells. Collectively, these findings suggest that CCDC167 has high potential as a therapeutic target for breast cancer.
Insights
Coiled-coil domain-containing protein 167 (CCDC167) is upregulated in breast cancer, promoting tumor growth. Targeting CCDC167 may offer a new therapeutic strategy for breast cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Breast cancer is a leading cause of new cancer cases in American women, with estrogen receptor (ER)-positive cancers playing a significant role.
- Estrogen's crucial role in ER-positive breast cancer necessitates identifying novel therapeutic targets and understanding downstream pathways.
- The specific role of coiled-coil domain-containing protein 167 (CCDC167) in breast cancer development and progression remained largely uncharacterized.
Purpose of the Study:
- To investigate the role of CCDC167 in breast cancer.
- To determine if CCDC167 expression correlates with patient prognosis.
- To evaluate CCDC167 as a potential therapeutic target for breast cancer.
Main Methods:
- Bioinformatics screening using multiple databases (ONCOMINE, MetaCore, IPA, Kaplan-Meier Plotter).
- Analysis of CCDC167 expression levels in relation to breast cancer patient prognoses.
- Experimental validation including CCDC167 knockdown and assessment of its effect on cancer cell growth and proliferation.
- Investigation of CCDC167 expression changes in response to standard chemotherapy agents (fluorouracil, carboplatin, paclitaxel, doxorubicin) in MCF-7 cells.
Main Results:
- CCDC167 was found to be upregulated across various tumor types.
- High CCDC167 expression levels were significantly associated with poor prognoses in breast cancer patients.
- Knockdown of CCDC167 suppressed aggressive breast cancer growth and proliferation.
- Chemotherapy treatments led to decreased CCDC167 expression and suppressed MCF-7 cell growth.
Conclusions:
- CCDC167 plays a significant role in promoting breast cancer growth and progression.
- CCDC167 expression is a potential biomarker for predicting poor patient outcomes.
- CCDC167 represents a promising novel therapeutic target for breast cancer treatment.
More Related Videos
Related Concept Videos
Inhibition of Cdk Activity
Positive Regulator Molecules
Positive Regulator Molecules
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle
Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...

